Clinical trial Recruiting at 2 sites Interventional Ages 18 and up

Contact radiotherapy for rectal cancer treatment

Official title: Contact Radiotherapy for Rectal Cancer (CORRECT): a Multicenter Randomized Phase II Trial

Run by Karolinska University Hospital · NCT06501053 · Data updated 2026-11-12

This study is testing a new treatment for early rectal cancer that combines a type of radiation therapy with a shorter course of treatment to see if it can help preserve organs and cause fewer side effects than standard options.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment110 (estimated)
SponsorKarolinska University Hospital
Academic / other
Drugs / interventionschemotherapy, radiation
Locations2 sites (Stockholm, Solna and 1 other locations)
StatusRecruiting
StartedMarch 3, 2025
Main results expectedApril 2030
Study endsNovember 2032
Registry record updatedAugust 10, 2026
Trial IDNCT06501053 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and above with operable adenocarcinoma of the rectum classified as cT1-cT3ab, N0-N1, and accessible for endocavitary contact X-ray brachytherapy.

Probably not a fit

Patients with inoperable rectal cancer, advanced tumor stages, or significant comorbidities may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the effectiveness of a combination of Contact x-ray brachytherapy (CXB) and short-course radiotherapy (SCRT) in preserving organs for patients with early and early intermediate rectal cancer. Participants will be randomly assigned to receive either the standard treatment of CXB combined with chemoradiotherapy or the experimental treatment of CXB with SCRT. The primary goal is to determine if the new treatment is non-inferior in terms of the two-year organ preservation rate while potentially reducing side effects compared to existing therapies. This approach is particularly relevant for patients who may not tolerate more intensive treatments.

Why it matters

Potential benefit: If successful, this treatment could provide a less invasive option for rectal cancer patients, leading to better organ preservation and fewer side effects.

How similar studies have gone: While previous studies have shown promising outcomes with SCRT and CXB, this specific combination has not been tested in a randomized setting, making it a novel approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adenocarcinoma of the rectum classified as:
* cT1-cT3ab, \< 5 cm largest diameter and \< ½ circumference (MRI staging), N0-N1 (\<= 3 nodes \< 8mm diameter), M0
* Performance status (ECOG) 0-1
* Operable patient
* Tumor accessible to endocavitary contact X-ray brachytherapy with a distance from the lower tumor border to the anal verge ≤10 cm
* 18 years or above
* No comorbidity preventing treatment
* Patient having read the information note and having signed the informed consent
* Follow-up possible

Exclusion Criteria:

* Inoperable patient
* T3cd, T4, T≥ 5cm, Involvement of more than half of the bowel circumference
* Distance from the lower tumor border to the anal verge \>10 cm
* N2-status at diagnosis or N1 with any node\>= 8 mm diameter
* Patient presenting with metastasis at diagnosis (M1)
* Previous pelvic irradiation
* Tumor with extramural vascular invasion
* Poorly differentiated tumor
* Simultaneous progressive cancer
* Tumor invading external anal sphincter or growth within 1 mm of the levator
* Tumor within 1 mm from MRF (mesorectal fascia)
* Patient unable to receive CXB or CRT
* Any significant concurrent medical illness that in the opinion of the investigator would preclude protocol therapy
* Patient with history of poor compliance or current or past psychiatric conditions or severe acute or chronic medical conditions that would interfere with the ability to comply with the study protocol
* Concurrent enrolment in another clinical trial using an investigational anti-cancer treatment within 28 days prior to the first dose of study treatment
* Total DPD deficiency

Where it's running

  • Karolinska University Hospital, Theme Cancer, Dept of Pelvic cancer
    Stockholm, Solna, Sweden
    Recruiting
  • Uppsala University Hospital, Colorectal Surgery
    Uppsala, Sweden
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.